Psoriasis Drugs Market Size Worth USD 21.11 Billion by 2022

The global psoriasis drugs market size is expected to be valued at USD 21.11 billion by 2022, as per a new report by Grand View Research, Inc., experiencing a CAGR of 9.4% during the forecast period. Rising disease awareness, increasing number of reimbursement strategies for biologics, and advanced diagnostic and technological tools are likely to increase the adoption of psoriasis therapeutics.

Additionally, expanding base of patients suffering from psoriasis is anticipated to fuel growth prospects. The exact causative factors for psoriasis are undetermined; however, certain genetic and environmental factors may trigger the disease onset. Most available treatments aim to decelerate disease progression by stopping hyperproliferation of keratinocyte.

Psoriasis can be classified into five types: plaque, guttate, inverse, pustular, and erythrodermic. The types vary in terms of site of disease and characterization of lesions. Erythrodermic psoriasis is the rarest and plaque psoriasis is the most prevalent type affecting patients all over the world.

Incidence rate of psoriasis has witnessed a gradual rise over the years across various geographical locations. This increase can be attributed to genetic and environmental triggers as well as lifestyle changes. Rise in prevalence rates could also be associated with declining response or developing resistance to therapies for disease control.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/psoriasis-drugs-market

Further key findings from the report suggest:

• Tumor Necrosis Factor-inhibitors dominated the market in 2016 owing to its higher usage by healthcare practitioners and easy availability
• TNF-inhibitors are likely to lose market shares over the forecast period due to increasing preference for IL-inhibitor therapy to conventional TNF-inhibitors
• Interleukin-inhibitors is expected to register a lucrative CAGR of over 21.0% during the forecast period owing to improved safety and efficacy profiles of Interleukin-inhibiting drugs
• The U.S is the dominant region in the psoriasis market in terms of revenue in 2016 due to increasing number of patients seeking treatment and presence of well-established healthcare services
• Japan is expected to be the fastest growing region during the same period due to growing awareness about the disease among the populace
• Some of the key players in this industry are AbbVie Inc.; Amgen Inc.; Johnson & Johnson; Novartis AG; Eli Lilly & Company; AstraZeneca; Celgene Corporation; UCB; and Merck.

Sustained Release Excipients Market Size Worth USD 1.6 Billion By 2026

The global sustained release excipients market size is expected to reach USD 1.6 billion by 2026 at a 7.1% CAGR during the forecast period, according to a new report by Grand View Research, Inc. Increasing focus on novel drug delivery R&D and rising adoption of extended release formulations for treatment of chronic diseases are major factors driving the market.

Use of sustained release drug formulations provides patients relief from these symptoms and helps maintain desired therapeutic drug levels in the body. In comparison to conventional drugs, sustained drug release technologies provide a wide range of benefits. Reduced dosage frequency, improved patient compliance, maintenance of constant level of drug in blood plasma, lower instances of toxicity due to overdose, and higher cost-effectiveness in the long run are some of the major advantages of using this technology.

Global rise in incidence of chronic and infectious diseases has also resulted in antibiotic resistance, which negatively affects the market for conventional dosage forms. Thus, alternative methods to manage and treat these diseases are being implemented. Use of sustained release formulations has been widely accepted among physicians in order to combat antibiotic resistance. Since these formulations create desired therapeutic drug levels in blood plasma and reduce dosage frequency, they are the preferred choice of formulation among physicians, which increases their demand.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/sustained-release-excipients-market

Further key findings from the report suggest:

• Polymers formed the largest revenue grossing segment by product type in 2017 and is anticipated to grow at a lucrative rate during the forecast period. This is due to its high adoption in sustained release formulations as they provide greater strength and improved shelf-life
• In terms of route of administration, the oral segment held the dominant share in 2017 and is projected to witness steady growth to retain its lead throughout the forecast period
• Transdermal technology is expected to exhibit the highest CAGR during the forecast period owing to its escalating usage. It minimizes various limitations associated with oral and parenteral route of administrations
• North America dominated the overall market in 2017 due to well-developed research infrastructure and presence of leading pharmaceutical and biopharmaceutical companies
• Asia Pacific is spearheading revenue growth, with Japan, China, and India at the forefront
• Some of the key companies in the market are Coating Place, Inc.; Depomed, Inc.; Corium International, Inc.; Capsugel; Aradigm Corporation; Orbis Biosciences, Inc.; and Alkermes plc.

Migraine Drugs Market Size Worth USD 7.8 Billion by 2025

The global migraine drugs market size is expected to be valued at USD 7.8 billion by 2025, as per a new report by Grand View Research, Inc., exhibiting an 18.0% CAGR during the forecast period. The market is largely driven by factors such as rise in disease prevalence, development of novel therapies, lifestyle changes, and hormonal medications.

Migraine is a debilitating neurological disease characterized by recurrent attacks of severe throbbing head pain that can last for more than three days. Migraine pain may get worse on movement, preventing the patient from carrying out normal, day-to-day activities. In about one-third of attacks, both sides of the head, face, or neck are affected.

Over the past five years, the global migraine drugs market has been relatively stagnant, with the market mainly dominated by usage of generic triptans and other off-label drugs. Majority of the currently prescribed drugs for both acute and preventative treatment are associated with poor efficacy and an unfavorable side-effect profile.

Launch of Amgen/ Novartis’ CGRP mAb Aimovig and Teva Pharma’s Ajovy is the first step toward revolutionizing the treatment paradigm of migraine prevention. For drug manufacturers likely to enter the market by 2019, such as Eli Lilly, Alder BioPharma, and Biohaven Pharma, pricing will be a key differentiating factor as all CGRP-based therapies have a similar efficacy and safety profile.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/migraine-drugs-market

Further key findings from the report suggest:

• Germany leads the European market, driven by rising disease prevalence, novel drug launches, and increase in R&D activities
• The acute migraine treatment market will be supported by rapid uptake of novel drug classes such as CGRP receptor antagonists and ditans currently under active investigation in multiple Phase II/III trials
• Biohaven’s rimegepant is expected to face competition from Allergan's ubrogepant, which has shown superior efficacy in Phase III trials compared to rimegepant
• Eli Lilly’s Phase III 5-HT1F receptor agonist Lasmiditan is expected to be a novel first-line non triptan acute treatment option for patients in whom triptans are contradicted
• Approximately 20% of patients seeking preventive treatment for migraine do not respond to available generic medications. Several biologics and small molecules drugs are undergoing active development to target high unmet needs in the preventive treatment segment
• Drugs with novel targets in early-phase development include AOBiome Therapeutics’ AOB-203 (antibacterial), Winston Pharma’s Dolorac (histamine H1 receptor antagonists), NeuroAxons’ NXN-188 (combination of NOS inhibitor and a triptan), and Biohaven’s BHV-3500 (gepant). These novel agents are under evaluation for both episodic and chronic migraine in multiple Phase I/II trials.

Cardiovascular Ultrasound Market Worth USD 1.87 Billion by 2025

The global cardiovascular ultrasound (CVUS) market size is expected to reach USD 1.87 billion by 2025, according to a new report by Grand View Research, Inc. It is anticipated to expand at a CAGR of 3.8% over the forecast period. Rising investment in Medtech industry, increasing R&D activities, and high prevalence of cardiovascular diseases are the key factors driving market growth.

Benefits associated with cardiovascular ultrasound over conventional methods include quick recovery, reduced span of hospitalization, and fewer post-operative complications. These benefits along with rising geriatric population are expected to propel demand of cardiovascular ultrasound diagnosis over the forecast period.

North America captured the largest market share in 2017. Favorable reimbursement framework and presence of a large number of industry players are some of the major factors which can be attributed to the regional growth. Rising geriatric population coupled with sophisticated healthcare infrastructure are expected to further fuel market growth in the region. Furthermore, increasing health awareness is driving the demand.

Some of the key players in the cardiovascular ultrasound market include Philips; GE Healthcare, Inc.; Hitachi; Fujifilm Medical Systems; Siemens Healthcare; and Canon Medical Systems Corporation.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/cardiovascular-ultrasound-system-market

Further key findings from the report suggest:

• Cardiovascular ultrasound market was valued at USD 1.38 billion in 2017 and is expected to grow lucratively over the forecast period
• Fetal echocardiography segment is anticipated to expand at the fastest CAGR
• Doppler segment was valued at USD 0.6 billion in 2017 and is anticipated to rise at a lucrative CAGR during the forecast period

• Ambulatory care centers segment is expected to witness the fastest CAGR in the forthcoming years.

Intravascular Ultrasound Market Size Worth USD 3.53 Billion by 2025

The global intravascular ultrasound (IVUS) market size is expected to reach USD 3.53 billion by 2025 at a 7.6% CAGR during the forecast period, according to a new report by Grand View Research, Inc. Rising investments in the medtech industry, increasing R&D activities, and surge in product launches are key factors driving the market.

Emerging economies have been offering new investment avenues to global market players. Developing healthcare infrastructure and increasing patient pool are driving demand for advanced medical devices in these countries.

Point of contact (POC) ultrasound is used for diagnostic procedures generally involving portable ultrasound devices. It is relatively cheaper and can be widely used in patient care. IVUS ultrasound is one such device, which is smaller and can be used to detect abnormalities in the vascular system.

Some of the key players in this market are Koninklijke Philips N.V.; GE Healthcare; Hitachi, Ltd., Fujifilm Medical Systems; Boston Scientific Corporation; Siemens Healthineers; and Canon Medical Systems Corporation.In June 2017, GE Healthcare and Heartflow announced a partnership for the diagnosis and treatment of coronary artery disease.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/intravascular-ultrasound-ivus-devices-market

Further key findings from the report suggest:

• The intravascular ultrasound market was valued at USD 1.98 billion in 2017 and is expected to grow lucratively over the forecast period
• By product, the accessories segment is anticipated to grow at the fastest rate over the forecast period. It is also the largest product segment
• On the basis of end use, the diagnostic centers segment is anticipated to register the fastest growth over the forecast period, owing to increasing establishments of standalone diagnostic centers
• Asia Pacific is expected to exhibit the highest CAGR of 9.1% over the forecast period owing to improved healthcare infrastructure, rising disposable income, and investments from global market players.

Biopharmaceuticals Contract Manufacturing Market Worth USD 21.7 Billion By 2025

The global biopharmaceuticals contract manufacturing market size is expected to reach USD 21.7 billion by 2025, according to a new report by Grand View Research, Inc., registering a CAGR of 7.5% during the forecast period. Growing biopharmaceutical pipeline and lack of adequate manufacturing capabilities are two key factors driving partnerships between large molecule manufacturers and contract manufacturing organizations (CMOs). Contract manufacturers are engaged in broadening their service portfolio to meet companies’ demand with respect to regulatory standards and new services.

Reliance of companies on CMOs for production of biologics and biosimilars is expected to rise over the forecast period as a consequence of changes adopted by CMOs. This is evident through growing investments in collaborations of companies with CMOs as well as continuous efforts taken up for broadening service portfolios.

The growth of CMOs is highly dependent on promising opportunities offered by the biopharmaceutical industry, bioprocessing industry, and contract service industry. Expansion of fill-and-finish services and increasing robustness of venture capital investments in the life science sector are important opportunities that are anticipated to drive the market.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/biopharmaceuticals-contract-manufacturing-market

Further key findings from the report suggest:

• Based on source, mammalian-based biopharmaceutical contract manufacturing captured the largest market share owing to high penetration of mammalian expression systems for biologics development
• By service, upstream and downstream services accounted for the largest revenue share. Complexities associated with these steps pronounces demand for established contract manufacturers to ensure manufacturing processes compliant with regulatory standards
• Biologics contract manufacturing dominated the market based on product owing to higher demand for biologics production. However, the biosimilar segment is slated to exhibit a lucrative CAGR due to cost-saving advantages associated with its development
• Presence of effective regulatory framework for biologics development in U.S. has resulted in North America market accounting for the dominant share in 2017. However, Asia Pacific is expected to emerge as the fastest growing regional market, with developing economies expanding at a substantial pace and incorporating developments to sustain the competition
• Several international companies are seeking outsourcing of biopharmaceutical production to Asian countries owing to continuous expansion of Asian CMOs that offer services at a reduced price, compared to service providers based in western countries
• Some of the key service providers are Boehringer Ingelheim GmbH; Lonza; Samsung BioLogics; and FUJIFILM Diosynth Biotechnologies U.S.A., Inc.

Nucleic Acid Isolation & Purification Market Worth USD 3.6 Billion By 2025

The global nucleic acid isolation & purification market size is expected to reach USD 3.6 billion by 2025, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 6.8% during the forecast period. Decreasing cost of genetic sequencing, ongoing developments in genetics, personalized medicine, and diagnostics, and increasing automation and technological advancements in instruments and tools used for isolation and purification of polynucleotides are some of the key factors driving this market.

Nucleic acid isolation and purification is the most basic step deployed in any biological research. Extraction, isolation, and purification of DNA and RNA are very crucial and need the help of experts. These techniques are mostly used in cloning, sequencing, genetic engineering, life science research, forensics, agriculture, and other fields.

Utilization of nucleic acids has gone beyond mere storage of genetic information and protein synthesis. These biological moieties can be used in myriad healthcare domains such as gene therapy, therapeutics and diagnostics, precision medicine, and forensics.

Over the years, scientists have been able to separate and purify nucleic moieties such as mRNA, miRNA, plasmid DNA, and genomic DNA. This is helpful in studying diseases and their pathologies at a genetic level in detail, which in turn, has proved helpful in designing therapeutics and diagnostics for several life threatening diseases. The detachment, disengagement, ligation, and purification of nucleic acids has become a lot easier than before, thanks to technological advancements and increasing use of DNA/RNA sequencing.

Various methods are used for the isolation and purification of nucleic acids such as silica based, magnetic bead based, and reagent based. Magnetic bead-based isolation and purification has become increasingly popular among researchers. These techniques and tools are utilized by diagnostic labs and clinics, pharmaceutical and biotech companies, scholastic research institutes, and hospitals.

North America currently holds the largest share in this market, followed by Europe. Asia is likely to register the fastest growth owing to its rapidly expanding economy, rising healthcare expenditure, and increasing government financing in research projects.

High cost of instruments that are utilized as part of the methodology for isolation and purification of nucleic acids is one of the key challenges in the market, especially in emerging countries. Major players in this market include QIAGEN; Danaher Corporation; Thermo Fisher Scientific, Inc.; Agilent Technologies Inc.; Bio-Rad Laboratories Inc.; and Promega Corporation.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/nucleic-acid-solation-and-purification-market

Further key findings from the report suggest:

• Rapid advancement in the application of genetics in sequencing and different healthcare domains is expected to drive this market
• Surge in demand for automated instruments and tools for nucleic acid isolation and purification is also benefitting market growth
• High cost of instruments and ambiguous reimbursement policies in some countries for genetic testing and research are expected to emerge as key challenges in the market
• Application of nucleic acid isolation & purification technologies in oncology is expected to expand at a CAGR of 7.8% during the forecast period
• Large number of technology providers, better healthcare infrastructure and facilities, greater patient awareness, and faster adoption of advanced technologies such as next-generation sequencing are responsible for market growth in North America and Europe